USD 9.28
(33.91%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 22.91 Million USD | 1720.86% |
2022 | -1.41 Million USD | 98.7% |
2021 | -108.5 Million USD | 27.52% |
2020 | -149.7 Million USD | -3.72% |
2019 | -144.33 Million USD | 71.48% |
2018 | -506.12 Million USD | -4305.28% |
2017 | -11.48 Million USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 30.3 Million USD | 32.23% |
2024 Q2 | 33.33 Million USD | 9.98% |
2023 Q4 | 22.91 Million USD | 9.3% |
2023 Q3 | 20.96 Million USD | 53.71% |
2023 Q2 | 13.64 Million USD | 258.15% |
2023 Q1 | 3.8 Million USD | 369.38% |
2023 FY | 22.91 Million USD | 1720.86% |
2022 Q4 | -1.41 Million USD | -118.81% |
2022 Q2 | 15.08 Million USD | 1508399900.0% |
2022 Q1 | 1.00 USD | 100.0% |
2022 FY | -1.41 Million USD | 98.7% |
2022 Q3 | 7.51 Million USD | -50.15% |
2021 Q1 | 18.07 Million USD | 114.71% |
2021 Q2 | 13.5 Million USD | -25.32% |
2021 FY | -108.5 Million USD | 27.52% |
2021 Q3 | 766 Thousand USD | -94.33% |
2021 Q4 | -97.11 Million USD | -12778.07% |
2020 Q4 | -122.89 Million USD | -12289100100.0% |
2020 Q3 | 1.00 USD | 0.0% |
2020 Q1 | 1.00 USD | 100.0% |
2020 Q2 | 1.00 USD | 0.0% |
2020 FY | -149.7 Million USD | -3.72% |
2019 Q2 | 1.00 USD | 0.0% |
2019 FY | -144.33 Million USD | 71.48% |
2019 Q4 | -131.5 Million USD | -13150600100.0% |
2019 Q3 | 1.00 USD | 0.0% |
2019 Q1 | 1.00 USD | 100.0% |
2018 Q1 | -42.53 Million USD | -270.2% |
2018 FY | -506.12 Million USD | -4305.28% |
2018 Q4 | -506.12 Million USD | -50612300100.0% |
2018 Q3 | 1.00 USD | 0.0% |
2018 Q2 | 1.00 USD | 100.0% |
2017 Q1 | 8.73 Million USD | 202.2% |
2017 Q2 | - USD | -100.0% |
2017 FY | -11.48 Million USD | 0.0% |
2017 Q4 | -11.48 Million USD | -182.7% |
2017 Q3 | 13.89 Million USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q4 | -8.54 Million USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Editas Medicine, Inc. | - USD | -Infinity% |
Dynavax Technologies Corporation | 53.29 Million USD | 56.992% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 70.392% |
Perrigo Company plc | 1.14 Billion USD | 97.991% |
Illumina, Inc. | 587 Million USD | 96.096% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.55% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -120.97% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.725% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Heron Therapeutics, Inc. | 42.11 Million USD | 45.573% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.112% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
Waters Corporation | 516.23 Million USD | 95.56% |
Biogen Inc. | 2.52 Billion USD | 99.093% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -108.392% |
Adicet Bio, Inc. | - USD | -Infinity% |
Cara Therapeutics, Inc. | 2.82 Million USD | -712.442% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 65.075% |
FibroGen, Inc. | 41.56 Million USD | 44.86% |
Agilent Technologies, Inc. | 1.03 Billion USD | 97.777% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 74.29% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 61.607% |
Myriad Genetics, Inc. | 20.1 Million USD | -14.025% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 99.106% |
Abeona Therapeutics Inc. | -2.44 Million USD | 1037.766% |
Mettler-Toledo International Inc. | 385.86 Million USD | 94.06% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 97.93% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 96.898% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 19.37% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -136.132% |
Verastem, Inc. | - USD | -Infinity% |
Nektar Therapeutics | 16.1 Million USD | -42.345% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -51.43% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 92.901% |
OPKO Health, Inc. | 65.69 Million USD | 65.114% |
Exelixis, Inc. | 17.32 Million USD | -32.304% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | 40.159% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -196.494% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 12.02 Million USD | -90.61% |
Imunon, Inc. | - USD | -Infinity% |
Blueprint Medicines Corporation | 21.22 Million USD | -7.991% |
Insmed Incorporated | 83.24 Million USD | 72.469% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 82.039% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -20.146% |
TG Therapeutics, Inc. | 39.82 Million USD | 42.448% |
Incyte Corporation | 62.97 Million USD | 63.604% |
Emergent BioSolutions Inc. | 328.9 Million USD | 93.032% |